spacer
home > ict > winter 2009 > chain reactions
PUBLICATIONS
International Clinical Trials

Chain Reactions

 

Management of cold chain clinical supplies presents sponsor companies with significant logistical challenges, especially considering the global nature of distribution to many less developed regions and emerging markets. When investigational products are shipped, supplies are subject to various factors which may influence the way in which temperature-controlled shipping systems may operate. These variables include a myriad of external temperature ranges, supply routes, transit time, and availability of stability data and people.

The nature of clinical trial shipments means that they are exposed to more risks than commercial shipments due to their urgency, diverse destinations, shipping methodologies or routes and variable shipment quantities. However, the goal still remains to ensure a consistent flow of material arriving at the site in a condition which is fit for its intended use.

When contemplating cold chain logistics, there are a number of elements to take into consideration:

  • Packaging for maintenance of temperature control – active and passive shipping systems
  • Use of monitoring devices
  • Courier selection and transit time
  • Planning for deviations

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Jonathan Calderwood is the Global Marketing Manager for Almac Clinical Services (Almac Group). He was educated in Queen’s University, gaining a BSc in Biochemistry, and he holds a Post Graduate Diploma in Computer Science and in Marketing, and is a member of the Chartered Institute of Marketing. Jonathan has extensive experience in clinical trial supply production and project management, as well as in the business development field.

spacer
Jonathan Calderwood
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market explored ahead of CPhI MEA

Saudi Arabia’s pharmaceutical market expected to grow at a CAGR of 5.5% until 2023. Growing population, increase in non-communicable diseases and major investment in new hospitals, clinics and treatments driving growth
More info >>

White Papers

Maximize the ROI of Your Post-Approval Research

Bioclinica

Expenditures in post-approval (Phase IV) research are going up across the pharmaceutical, biotech and medical device industries. Given the resources you’ve committed to post-approval research, you may be wondering if you’re getting the greatest possible return on your investment. Discover how to harness the power of post-approval research to increase data collection, reduce resource burn, save money, and maximize your ROI!
More info >>

 
Industry Events

Clinical Trials Europe | Partnerships, Outsourcing, Operations & Technology

27 August - 21 November 2019, Barcelona, Spain

On 19-21 November 2019, the clinical trial community's most influential stakeholders will be meeting in Barcelona to discuss the evolving landscape, honing in on what it takes to harness true value from partnerships, outsourcing, operations, technology and early clinical development, for a faster, more efficient route to market.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement